140406-65-1Relevant academic research and scientific papers
Preparation and application of sulfanilamide and benzothiazole compounds containing tetrahydroisoquinoline
-
Paragraph 0026-0027, (2020/04/17)
The invention discloses a sulfanilamide compound, containing tetrahydroisoquinoline, shown as figure 1, and a benzothiazole compound, containing tetrahydroisoquinoline, shown as figure 2, and application of the sulfanilamide compound and the benzothiazole compound as novel protein arginine methyltransferase 5 inhibitors.
PRMT5 INHIBITORS AND USES THEREOF
-
Paragraph 0212-0213, (2019/04/05)
Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.
Rational Design, synthesis and biological evaluation of novel triazole derivatives as potent and selective PRMT5 inhibitors with antitumor activity
Zhu, Kongkai,Shao, Jingwei,Tao, Hongrui,Yan, Xue,Luo, Cheng,Zhang, Hua,Duan, Wenhu
, p. 775 - 785 (2019/07/22)
Protein arginine methyltransferase 5 (PRMT5) is responsible for the mono-methylation and symmetric dimethylation of arginine, and its expression level and methyl transferring activity have been demonstrated to have a close relationship with tumorigenesis, development and poor clinical outcomes of human cancers. Two PRMT5 small molecule inhibitors (GSK3326595 and JNJ-64619178) have been put forward into clinical trials. Here, we describe the design, synthesis and biological evaluation of a series of novel, potent and selective PRMT5 inhibitors with antiproliferative activity against Z-138 mantle cell lymphoma cell line. Among them, compound C_4 exhibited the highest potency with enzymatic and cellular level IC50 values of 0.72 and 2.6 μM, respectively, and displayed more than 270-fold selectivity toward PRMT5 over several other isoenzymes (PRMT1, PRMT4 and PRMT6). Besides, C_4 demonstrated obvious cell apoptotic effect while reduced the cellular symmetric arginine dimethylation levels of SmD3 protein. The potency, small size, and synthetic accessibility of this compound class provide promising hit scaffold for medicinal chemists to further explore this series of PRMT5 inhibitors.
COMPOUNDS USEFUL IN THE TREATMENT OR PREVENTION OF A PRMT5-MEDIATED DISORDER
-
Paragraph 00133, (2018/10/19)
The present disclosure relates to compounds suitable for the inhibition of protein arginine methyl-transferase (PRMT), in particular PRMT5. These compounds may be for use as therapeutic agents, in particular, agents for use in the treatment and/or prevent
Structure and Property Guided Design in the Identification of PRMT5 Tool Compound EPZ015666
Duncan, Kenneth W.,Rioux, Nathalie,Boriack-Sjodin, P. Ann,Munchhof, Michael J.,Reiter, Lawrence A.,Majer, Christina R.,Jin, Lei,Johnston, L. Danielle,Chan-Penebre, Elayne,Kuplast, Kristy G.,Porter Scott, Margaret,Pollock, Roy M.,Waters, Nigel J.,Smith, Jesse J.,Moyer, Mikel P.,Copeland, Robert A.,Chesworth, Richard
supporting information, p. 162 - 166 (2016/03/01)
The recent publication of a potent and selective inhibitor of protein methyltransferase 5 (PRMT5) provides the scientific community with in vivo-active tool compound EPZ015666 (GSK3235025) to probe the underlying pharmacology of this key enzyme. Herein, we report the design and optimization strategies employed on an initial hit compound with poor in vitro clearance to yield in vivo tool compound EPZ015666 and an additional potent in vitro tool molecule EPZ015866 (GSK3203591).
PRMT5 INHIBITORS AND USES THEREOF
-
Paragraph 00430, (2014/07/08)
Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described
PRMT5 INHIBITORS AND USES THEREOF
-
Paragraph 00220, (2014/07/08)
Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.
PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF
-
Paragraph 00251, (2014/07/08)
Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5- mediated disorders are also described.
Anticancer agents
-
Page/Page column 9, (2008/06/13)
Disclosed herein is a method for suppressing the growth of cancer cells in a mammal in need of such treatment comprising administering to said mammal a cancer cell suppressing amount of a diphenylmethylpiperazine represented by the following general formu
ANTICANCER AGENTS
-
, (2008/06/13)
Diphenylmethylpiperazine derivatices which are anticancer agents characterized by being compounds represented by general formula [1], salts thereof, derivatives thereof or prodrugs thereof: [1] wherein R represents (α) or (β). Compared with the conventional anticancer agents, these anticancer agents are less toxic and exert an excellent carcinostatic effect on various solid cancers. Moreover, these anticancer agents inhibit the proliferation of fibroblasts, which makes them efficacious against pulmonary fibrosis and proliferative keloid lesion.
